T cell depletion of allogeneic stem cell grafts is a highly T cell depletion using the murine monoclonal antibody effective means of reducing the severity and incidence of (moAb) T 10 B 9 is unique in that the T cell receptor acute GVHD. 1 The beneficial effects of T cell depletion are (TCR)␥␦ bearing subset is relatively spared compared counterbalanced by increased graft rejection and, for some to the TCR␣␤ ؉ subset. We evaluated the probabilities diseases, a marked increase in the rate of leukemia of engraftment, acute and chronic graft-versus-host disrelapse. 2,3 It has been hypothesized that acute GVHD may ease (GVHD), relapse, and survival in 273 recipients of be decreased without an increase in leukemia relapse by marrow T cell depleted using T 10 B 9 . Sixty-two patients received marrow from an HLA-identical sibling, 54
T cell depletion of allogeneic stem cell grafts is a highly T cell depletion using the murine monoclonal antibody effective means of reducing the severity and incidence of (moAb) T 10 B 9 is unique in that the T cell receptor acute GVHD. 1 The beneficial effects of T cell depletion are (TCR)␥␦ bearing subset is relatively spared compared counterbalanced by increased graft rejection and, for some to the TCR␣␤ ؉ subset. We evaluated the probabilities diseases, a marked increase in the rate of leukemia of engraftment, acute and chronic graft-versus-host disrelapse. 2, 3 It has been hypothesized that acute GVHD may ease (GVHD), relapse, and survival in 273 recipients of be decreased without an increase in leukemia relapse by marrow T cell depleted using T 10 B 9 . Sixty-two patients received marrow from an HLA-identical sibling, 54 depletion of selected subsets of T cells from the donor patients received partially matched related donor margraft. 4 In contrast, high rates of graft rejection appear to be row and 157 patients received unrelated donor marrow.
most strongly associated with methods resulting in rigorous Limiting dilution analysis (LDA) was used to estimate depletion of all lymphoid cells. 5 Engraftment of T celltotal clonable T cell dose in all patients and a modified depleted (TCD) marrow is also influenced by the intensity LDA using moAb-coated immunomagnetic beads was of the pretransplant conditioning regimen and by immunoused to estimate TCR␣␤ ؉ , CD4 + and CD8 ؉ T cells in suppressive treatment during the early post-transplant a subset of patients. TCR␥␦ ؉ cell dose was estimated period. 6 Both engraftment and acute GVHD rates are by flow cytometry. Cox proportional hazards regression influenced by donor/recipient relationship and histocompatmodels were used to assess the impact of T cell subset ibility. 3 The dose and/or subset of T cells needed to reduce dose/kg of body weight on outcome. We found a signifithe likelihood of rejection vs those which result in an unaccant association of TCR␥␦ ؉ T cell dose (P = 0.004), but ceptable incidence of acute GVHD is difficult to define. In not TCR␣␤ ؉ T cell dose or total clonable T cell dose, the absence of post-transplant chemoprophylaxis, as few as with the probability of engraftment. TCR␣␤ ؉ , CD4
؉ , 10 5 clonable T cells/kg appear sufficient to induce acute CD8 ؉ and total clonable T cell dose were significantly GVHD after an HLA-identical sibling transplant. 7 The dose associated (P Ͻ 0.001) with the risks of grade 2-4 acute associated with acute GVHD is less well defined for recipi-GVHD in recipients of marrow from related donors but ents of HLA disparate or unrelated transplants. 8, 9 not in recipients of marrow from unrelated donors. T 10 B 9 -1A3 (T 10 B 9 ) is an IgM moAb developed at the Neither total clonable T cell dose nor any T cell subset University of Kentucky, and has been used clinically for T dose was found to be significantly associated with cell depletion of donor marrow for more than 10 years. chronic GVHD, relapse or survival. The results confirm T 10 B 9 was originally characterized as a nonmitogenic antipreclinical studies showing TCR␥␦ ؉ T cells promote body recognizing an epitope of CD3. 10 However, subengraftment. TCR␥␦ ؉ T cells are not associated with sequent studies of this antibody suggest a selective specian increased risk of acute GVHD while TCR␣␤ T cells ficity for cells bearing the ␣␤ form of the T cell receptor are associated with acute GVHD but not engraftment in (TCR). 11 Our own data indicate that while T 10 B 9 binds to recipients of marrow grafts T cell depleted using T 10 B 9 .
all T cells, the TCR␥␦ subset is relatively spared following These findings support the hypothesis that T cell subsets complement-mediated lysis of antibody-treated marrow.
12 differentially contribute to alloengraftment and GVHD. TCR␥␦ + T cells have been shown to be capable of Keywords: bone marrow transplant; T cell depletion; mediating acute GVHD, causing graft rejection, and graft-versus-host disease; limiting dilution assay; TCR␥␦ + promoting engraftment in murine TCD transplantation T cells; TCR␣␤ + T cells models. [13] [14] [15] However, the role of this subset in clinical transplantation has not been well defined. Our clinical results using T 10 B 9 for TCD together with cyclosporine prophylaxis show a low incidence of grades 2-4 acute 1070 known at the time of analysis. Differences at HLA-A, -B, -DRB1 and -DQ were considered as disparities. The HLA class and number of antigens mismatched are shown in Table 1 .
T cell depletion
(n = 195 grafts) we utilized Terasaki culture plates with a 10 l capacity (Robbins Scientific, Sunnyvale, CA, USA) Bone marrow mononuclear cells (BMMC) were prepared and filled the 40 inner wells of two separate plates at each by density gradient separation of buffy coat fractions of the responder cell concentration. The outer wells of these plates harvested marrow. The cells were preincubated with T 10 B 9 were filled with PBS to reduce evaporation. After this date for 30 min at 4°C in RPMI-1640 tissue culture medium (n = 78 grafts) we used a 25 l capacity well plate which containing 5% fetal bovine serum (FBS) for all except 15 has a much lower potential for evaporation and allowed the cases where preincubation was in medium containing 5% use of all 72 wells. Thus, 72-80 replicate wells were used human serum albumin (HSA). Prescreened baby rabbit for each of eight responder cell concentrations ranging from serum (C-6 Diagnostics, Mequon, WI, USA) was added as 100 to 1 cell/well for non-TCD samples and from 1000 to a source of complement and 150 Kunitz Units/ml of Type 25 cells/well for TCD samples. The plates were incubated II DNase (Sigma Chemical Company, St Louis, MO, USA) at 37°C in a well humidified atmosphere of 5% CO 2 for was added to prevent cell clumping. The reaction was con-14-16 days and were scored for growth by microscopic tinued, with frequent mixing, for 90 min at 37°C for provisual inspection. cedures performed prior to January 1994 when the incu-
The development of the subset assay has been bation temperature was changed to 20-24°C. There was no described. 12 Briefly, Dynabeads M-450 (Dynal) conjugated effect on log depletion of clonable T cells due to this with a goat-anti-mouse IgG were bound wth BMA-031 for change in temperature. The BMMC concentration during assessment of TCR␣␤ + T cells. Anti-CD4 and anti-CD8 the purging step was 15 × 10 6 cells/ml with a total antibody beads were obtained pre-conjugated from Dynal. A total of protein content of 4 g/ml. The TCD cells were washed 2 × 10 4 beads in a volume of 5 l were added to each growfree of the purging reagents and were suspended in an isoing well to be analyzed and the plates were incubated for tonic infusion grade salt solution containing 2.5% HSA for 30 min at 4°C with circular rotation at 50 r.p.m. After setinfusion. Samples for flow cytometry and LDA assessment tling for 10 min each plate was fixed to a similar sized temwere taken from the BMMC fraction before depletion and plate of samarium cobalt magnets. The nonadherent cells from the product immediately after depletion.
were washed away by PBS. Residual PBS in the wells was removed by 'flicking' and each well was filled with 20 l of fresh PBS. The plates were detached from the magnets Flow cytometry and scored microscopically for rosettes of beads and cells. The BMMC were tested before and after depletion using a A minimum of 36 wells at each of four responder cell conpanel of PE-or FITC-conjugated antibodies including anticentrations in which there were growing wells was used to CD45, CD3, CD5, CD4, CD8, CD19, CD56, obtained from estimate the subset frequency. Coulter Immunology (Hialeah, FL, USA) and TCR␣␤ (BMA-031) and TCR␥␦ (5A6.E9) obtained from T-Cell Outcomes Diagnostics (Woburn, MA, USA), with appropriate isotype controls. Post-depletion flow samples were incubated in Patients surviving у21 days who did not reach an absolute RPMI-10% FBS for 60 min at 37°C and washed once to neutrophil count (ANC) у0.5 × 10 9 /l, stable over 3 conremove residual bound T 10 B 9 prior to testing. Red blood secutive days were considered to have primary graft failure. cells were lysed using a 2 min incubation with FACS lysis Patients with counts reaching but subsequently falling buffer (Becton Dickinson, San Jose, CA, USA) after stainbelow 0.5 × 10 9 /l without recovery during the first posting. Cells were suspended in PBS containing 0.02% NaN 3 , transplant month were considered early graft failures. Acute 1% BSA, and 1% formalin for analysis. T cell subsets were GVHD was defined as moderate to severe (grades 2-4) and assessed using a lymphocyte/blast region gate with percentchronic GVHD was classified as limited or extensive using ages expressed based on total marrow cells analyzed criteria previously described. 21 Patients surviving more than calculated as: subset % total marrow = subset % 21 days with engraftment were considered at risk for acute lymphocyte/blast gate × % of debris-free events gated. Only GVHD and patients surviving without relapse for у100 cells dual staining with CD3 and TCR␥␦ moAb were condays were considered at risk for chronic GVHD. Clinical sidered TCR␥␦ + . A minimum of 25 000 debris-free events relapse was evaluated in patients with malignant disease were analyzed using an Epics Profile flow cytometer and using standard criteria. Elite analysis software (Coulter Instruments). Debris-free events were increased to 50 000 or to 75 000 if gated events Statistical methods at the lower acquisition number fell below 2000 events. Absolute subset content was calculated by multiplying the LDA frequency determinations were performed by the total number of viable marrow cells infused by the subset method of 2 minimization as described by Taswell. 22 The percentage of the total marrow. Subset dose per kilogram LDA frequency estimates were corrected for cloning was calculated as the absolute subset content divided by efficiency based on the flow cytometry assessment of prethe patient weight in kilograms.
depletion CD3 + T cell frequency compared to predepletion total clonable T cell frequency. The correction factor was calculated as: correction factor = flow cytometry frequency Limiting dilution assays pre-depletion/total clonable T cell LDA frequency predepletion. LDA of total clonable cells was performed on pre-and post-TCD samples as described. 12 Prior to August 1994 Patient-, disease-, and treatment-related variables were compared in patients receiving a log 10 T cell dose/kg Ͼ together with the TCR␥␦ antibody, since a subset of TCR␥␦ + T cells may not express CD5.
24 median (5.5) vs р median using the 2 test for discrete variables or the Mann-Whitney U-test for continuous variTo estimate better the T cell content of marrow treated with T 10 B 9 we utilized a limiting dilution technique. The ables. Survival curves were calculated using the KaplanMeier method. The log-rank test was used for univariate efficiency of the LDA was determined by comparing the frequency of clonable T cells with the % of total CD3 + T comparisons.
Cox proportional hazards regression models using a forcells calculated from flow cytometry assessment of lymphocyte/blast gated cells in BMMC samples prior to ward stepwise selection procedure were used to evaluate the impact of patient-, disease-and transplant-related TCD. A cloning efficiency of 88 ± 4% (mean ± s.e.m.) (n = 273) was found with the major source of variation variables (shown in Table 1 ) on engraftment, acute and chronic GVHD, relapse and survival. 23 Total clonable cells being the feeder cell lot (not shown). The LDA frequency estimates were corrected for cloning efficiency to eliminate were assessed for all donor grafts, whereas T cell subsets were measured in a subset of cases. The statistical models this variability. The frequency of total clonable cells in the LDA of TCD samples was found to be consistently lower were constructed using the largest data set, total clonable cells, so as to identify significant covariants for the measthan the CD3 content based on flow assessment as shown in Table 2 (P Ͻ 0.00001, paired t-test). Immunomagnetic ured outcome with the highest degree of power. The log of the total clonable cell dose/kg of body weight was used as beads coated with antibody to TCR␥␦ + T cells were used to test 58 donor marrow grafts using the subset LDA. This a continuous variable in all steps of model selection. A significance level of 0.05 was used for inclusion of other assessment revealed that the cloning efficiency for the spared TCR␥␦ + T cells was only 25 ± 3% accounting for variables. Models including the covariables found to be significant for total clonal T cell dose were then independently some of the difference between CD3 + T cells detected by flow cytometry and the total clonal cell frequency. The recalculated substituting (1) log TCR␣␤ + T cell dose/kg, (2) log TCR␥␦ + T cell dose/kg, (3) log CD4 + T cell cloning efficiency of TCR␥␦ + T cells in TCD samples could be improved to 80 ± 5% (n = 3) with the addition of IL-4 dose/kg and (4) log CD8
+ T cell dose/kg, for total clonable cells. Proportional hazards were tested using a time-depen-(100 U/ml) to the LDA culture medium, without affecting the frequency of TCR␣␤ + T cells indicating that the dent covariant model and models were stratified where appropriate. First order interactions were considered. Data TCR␥␦ + T cells detected by flow cytometry were viable and clonogenic. Due to the low cloning efficiency for on total clonable T cell dose were available for all 273 patients. TCR␥␦ + T cell dose was determined by flow cyto-TCR␥␦ + T cells in the standard LDA, and the relatively high percentage of easily detected CD3 + TCR␥␦ + T cells metry in 225 patients. The immunomagnetic bead assay was used to assess TCR␣␤ + T cell dose for 159 patients, in lymphocyte gated marrow post-TCD (3.1 ± 3.0%), flow cytometry was used to estimate TCR␥␦ + T cells in this and CD4 and CD8 T cell dose for 140 patients.
Engraftment models required adjustment for diagnosis study. We reassessed our earlier findings regarding the speciand were stratified by year of transplant. Acute GVHD models were adjusted for age, presence of a class II misficity of depletion by T 10 B 9 in this larger data set. 12 For this analysis we excluded 16 cases included in the statistical match and presence of a class I + class II mismatch. Chronic GVHD models were adjusted for patient age.
analysis, in which the purging medium included HSA as a substitute for FBS in the preincubation step. This was Relapse models were adjusted for disease, disease stage and HLA match. Survival models were adjusted for patient age, because in eight of the 16 treatments, TCD was less than our previous lower limit of one log and subsequently this and the presence of HLA mismatch. modification of the protocol was abandoned. The efficiency and specificity of TCD using T 10 B 9 in our standard fashion is shown in Table 2 with the results expressed as the freResults quency of cells in the total BMMC population, and in the lymphocyte/blast gated cells before and after depletion. Efficiency and specificity of TCD using T 10 B 9 The results confirm a more complete elimination of the TCR␣␤ + subset, with a log depletion of 1.9 ± 0.3 compared Estimation of T cell content before and after purging using T cell-specific moAbs poses technical difficulties related in to 0.7 ± 0.5 logs of TCR␥␦ + T cells (P Ͻ 0.00001, paired t-test). The average dose/per kg of total clonable T cells part to the specificity of the antibody being used. T 10 B 9 binds to both TCR␣␤ + and TCR␥␦ + T cells, 12 but selecwas 4.7 × 10 5 /kg and was 3.1 × 10 5 for TCR␣␤ + T cells. The LDA was somewhat biased towards the growth of tively spares a portion of the TCR␥␦ + population when used in complement-mediated lysis techniques as illustrated in CD4 + T cells. Flow assessment showed a CD4:CD8 ratio of 1.2 ± 0.6 vs 3.5 ± 1.4 by LDA prior to T cell depletion. Figure 1 . CD3 and the TCR␣␤ antigen were found to be dimly expressed on spared TCR␣␤ + T cells making exact LDA showed a greater log depletion of CD4 + T cells which resulted in a CD4 : CD8 ratio of 2.3 ± 0.9 in the TCD quantification by flow techniques difficult, whereas, CD3 and TCR were not modulated on TCR␥␦ + T cells. 12 Howsamples. ever, TCR␥␦ bright cells were selectively lysed as illustrated in Figure 1 . CD5 monoclonal antibodies were used Univariate analysis of outcomes in dual analysis with TCR␣␤ for monitoring of TCD grafts due to reciprocal inhibition of binding when CD3 and
Univariate analysis of total clonable T cell dose did not reveal any significant differences in the probability of TCR␣␤ are used together. CD5 antibody was not used 
Figure 1
Flow cytometry assessment of bone marrow mononuclear cells (BMMC) before and after complement-mediated lysis using T 10 B 9 . Analysis was performed using a lymphocyte/blast gate shown in (a). A total of 40 000 debris-free events were collected pre-and post-depletion. The pre-depletion lymphocyte/blast gate represents 30.4% of the total events and post-depletion represents 10.6% of the total events. Two color histograms of a constant 5000 gated events pre-and post-depletion are shown in (b). The numbers represent the percentage of events in the quadrants in which they appear. Predepletion CD3 expressed as a percentage of total BMMC was 19.9% and TCR␥␦ was 1.1%. Post-depletion total BMMC CD3 was 1.1% and TCR␥␦ was 0.6%. CD5 + B cells as well as CD5 + TCR␥␦ + T cells contribute to the TCR␣␤ − CD5 + events in the lower panels.
engraftment, acute or chronic GVHD, relapse at 2 years or Multivariate analysis of engraftment survival at 2 years in patients who received more or less than the median (5.50 log) total log clonable T cell dose All patients were evaluable for engraftment. Fourteen patients who either never achieved an ANC у500 for 3 (not shown). This analysis did show that patients under the age of 16 years received higher T cell doses than older consecutive days (n = 10), or who lost their grafts during the first post-transplant month (n = 4) were considered graft patients (P = Ͻ0.001 by 2 analysis) most likely due to the higher dose of total marrow cells infused per kilogram failures. These included one infant with immune deficiency, four patients with ALL, two patients with ANLL, three (1.8 ± 0.8 × 10 8 for р16 years vs 0.9 ± 0.5 × 10 8 for patients older than 16 years) rather than a higher percentage patients with CML, one patient with MDS and three patients with severe aplastic anemia. Two of these 14 of T cells in the infused marrow. Table 2 Efficiency and specificity of T cell depletion using T 10 B 9 monoclonal antibody
Flow assessment Limiting dilution analysis
Pre-depletion % 16.3 ± 8.9 (65.1 ± 11.1) 1.0 ± 0.8 (4.1 ± 2.7) 11.4 ± 8.0 a 14.5 ± 7.6 11.1 ± 6.0 3.5 ± 2.0 Post-depletion % 0.9 ± 0.8 (9.8 ± 6.7) 0.3 ± 0.2 (3.1 ± 3.1) 0.4 ± 0.4 0.2 ± 0.3 0.2 ± 0.1 0.1 ± 0.1 Log depletion 1.3 ± 0.4 0.7 ± 0.5 1.7 ± 0.4 1.9 ± 0.4 1.9 ± 0.3 1.8 ± 0.3 Dose/kg × 10 5 11.7 ± 13.7
3.4 ± 4.1 4.7 ± 7.0 3.1 ± 6.3 2.0 ± 2.9 1.1 ± 2.7
The results are the mean and standard deviation from the assessment of 257 donor grafts treated by the standard depletion protocol as described in Materials and Methods. Data are expressed as the percentage of the indicated subset in the entire bone marrow mononuclear cell fraction and in the lymphocyte/blast gate (in parenthesis). The percentage of BMMC included in the lymphocyte gate was 24.4% ± 11.4% pre-depletion and 9.4 ± 5.5% post-depletion. LDA frequency estimates are corrected based on the flow assessment of CD3 + T cells in the pre-depletion bone marrow mononuclear cell fraction unless otherwise noted. Data for the TCR␣␤ subset are from 144 donor grafts and data for CD4 and CD8 subsets are from 125 donor grafts. Log depletion was calculated based on the difference between pre-depletion and post-depletion adjusted frequencies. a LDA frequency estimate for pre-depletion total clonable cells is not adjusted to the flow cytometry estimate.
Table 4
Effect of T cell dose/kg on the risk of acute grade 2-4 GVHD patients received grafts from a HLA-identical sibling. Cox regression models showed a significant association of log of the other T cell subset doses measured (Table 3) . Total clonable T cell dose and T cell subset dose was significantly associated with the risk of grades 2-4 acute from an unrelated donor. The effects are therefore shown separately by donor source in Table 4 . In recipients of related donor grafts, total clonable T cell dose, dose of chronic GVHD in multivariate analysis. In patients with TCR␣␤ + T cells and dose/kg of CD4 + and CD8 + T cell malignant disease the relative risk of relapse was found to subsets were highly associated with the risk of acute decrease with increasing T cell subset dose, but this effect GVHD. The relative risk of acute GVHD increased 6.4-did not reach statistical significance in multivariate analysis fold (95% confidence 2.7-15.1) with every log increase in adjusted for disease, disease stage, and HLA match. No TCR␣␤ + cell dose/kg (P = 0.001). There was no association significant associations of total T cell or T cell subset dose of TCR␥␦ + T cell dose with acute GVHD regardless of with survival were found. donor relationship.
Discussion

Multivariate analysis of chronic GVHD, relapse and survival
Determining the effect of T cell subset dose in human marNeither total clonable T cells nor any of the measured T row allografts has been difficult since measurement of low cell subsets was significantly associated with the risk of frequency populations in TCD marrow is technically complicated. In recent years, flow cytometry methods have been Consistent with both murine models, the multivariate analycontent of marrow depleted with T 10 B 9 we applied a limiting dilution culture system which has a high cloning sis of our clinical data indicated that the dose/kg of TCR␥␦ + T cells was associated with engraftment. The analysis also efficiency for TCR␣␤ + T cells. 26 We modified the LDA in order to determine more precisely the frequency of indicated no impact of TCR␥␦ + T cell dose on acute or chronic GVHD or relapse. These data confirm the preclini-TCR␣␤ + T cells and to determine the frequency of CD4 + and CD8 + subsets in TCD samples. 12 We applied both flow cal models in showing an association of TCR␥␦ + T cell dose with engraftment and suggest that the sparing of this cytometry and LDA techniques to determine if there was a differential effect of subset dose on graft outcome.
subset may contribute to the relatively high engraftment rate of marrow TCD with T 10 B 9 . The data further indicate The major findings were that engraftment was associated with TCR␦ + T cell dose but not with the dose of other T TCR␥␦ + T cells do not significantly contribute to the risk of GVHD in this setting. cell subsets measured and that acute GVHD was associated with total clonable dose, the dose of TCR␣␤ + , CD4 + and The Sloan-Kettering group, using an LDA for total clonable T cells similar to the one employed in this study CD8 + T cells but not with TCR␥␦ + T cell dose in recipients of grafts from related donors. The analysis was somewhat showed a critical dose of 10 5 T cells/kg above which there was a high risk of developing acute GVHD. 7 This strong complicated by the fact that not all 273 cases were tested for each of the T cell subsets. The subset LDA for TCR␣␤ + correlation was in the setting of HLA genotypic identity and the absence of prophylactic drugs for GVHD. Our data T cells was implemented prior to the development of LDA assessment of CD4 + and CD8 + subsets and technical limiare consistent in showing a relationship between T cell dose and acute GVHD but only in the setting of related donor tations prevented the assessment of all subsets for each donor graft. The outcome models were constructed from transplantation. After adjustment for known HLA disparity, the dose of total clonable T cells, TCR␣␤ + T cells as well the largest data set of total clonal T cell dose/kg and were recalculated using subset dose in place of total clonable T as CD4 + and CD8 + T cells were each strongly associated with the risk of acute GVHD in recipients of grafts from cells for the smaller patient groups for whom the individual T cell subset data were available. Sample bias may have related donors. Our patients tolerated higher doses of total clonable T cells than those reported by Kernan et al 7 and been introduced if technical failures in these assays occurred nonrandomly. However, an analysis restricted to there was considerable overlap in the dose/kg of all measured subsets between patients who did and who did not patients with both TCR␣␤ and TCR␥␦ subset data yielded results similar to those obtained with the larger data sets develop acute GVHD. This difference may be due in part to the use of CsA as additional GVHD prophylaxis in and confirmed the differential effect of T cell subsets on outcome.
our patients. atly reduced by T cell depletion of the marrow graft indicating that T cell dose does play a critical role in GVHD but may possess a more limited antigen repertoire (reviewed in Ref. 27 ). Complement-mediated lysis of bone risk. 16, 35 However, over the dose range of T cells infused to recipients of unrelated grafts TCD with T 10 B 9 , variables marrow using T 10 B 9 results in an average depletion of 1.9 ± 0.4 log of TCR␣␤ + T cells compared to 0.7 ± 0.5 log independent of T cell subset dose appear to influence more strongly the risk of acute GVHD as indicated by the lack depletion of the TCR␥␦ + T cell subset. This results in a similar dose of TCR␥␦ + and TCR␣␤ + T cells infused with of association of T cell dose with acute GVHD in this patient group. Donors and recipients of unrelated grafts are the marrow graft which allowed us to assess the potential effects of both major subsets on graft outcome. more likely to be disparate for minor histocompatibility antigens and MHC disparities undetected by the currently The role of TCR␥␦ + T cells in clinical transplant outcome has not been well defined. Circulating TCR␥␦ + T employed typing techniques are likely to exist. 36, 37 The T cell dose required to induce acute GVHD may be related cells have been found in increased numbers in some studies, [28] [29] [30] but the significance of this finding is unknown. to the degree and/or type of disparity present with lower doses required in the presence of both major and multiple Other data have suggested a potential role of TCR␥␦ + T cells in acute GVHD 28, 29 or as anti-leukemia effectors. 31 minor histocompatibility differences. This may explain the higher incidence of acute GVHD in recipients of unrelated Data from recently developed transgenic murine models indicate that clonal populations of TCR␥␦ + T cells are capgrafts receiving low T cell doses. The alloreactive potential of the infused T cells as well as the dose infused may also able of inducing acute GVHD, mediating graft rejection, and promoting engraftment. 13, 14 In this model target recogcontribute to the likelihood of acute GVHD in the setting of an unrelated transplant. [38] [39] [40] [41] nition is restricted by nonclassical class Ib histocompatibility antigens. Studies from our group using polyclonal We looked separately at the dose of CD4 and CD8 T cell subsets, since it has been shown that selective depletion TCR␥␦ + T cells derived from TCR␣␤ deletion mutants indicate that high doses of TCR␥␦ + T cells can facilitate of CD8 + T cells may be sufficient to reduce the incidence
